Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawagishi, Naoki, Suda, Goki, Sakamori, Ryotaro, Matsui, Takeshi, Onozawa, Masahiro, Yang, Zijian, Yoshida, Sonoe, Ohara, Masatsugu, Kimura, Megumi, Kubo, Akinori, Maehara, Osamu, Fu, Qingjie, Hosoda, Shunichi, Tokuchi, Yoshimasa, Suzuki, Kazuharu, Nakai, Masato, Sho, Takuya, Morikawa, Kenichi, Natsuizaka, Mitsuteru, Ogawa, Koji, Sakai, Hajime, Ohnishi, Shunsuke, Baba, Masaru, Takehara, Tetsuo, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546937/
https://www.ncbi.nlm.nih.gov/pubmed/36207368
http://dx.doi.org/10.1038/s41598-022-21315-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546937/
https://www.ncbi.nlm.nih.gov/pubmed/36207368
http://dx.doi.org/10.1038/s41598-022-21315-z

Ejemplares similares